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Interleukin 17This study was undertaken to evaluate the expression of inﬂammatory cytokines in patients with Paget's disease
of bone (PDB). Serum levels of tumoral necrosis factor-α, interleukin 1β, interleukin-6 and interleukin-17 were
measured in 51 patients with PDB and in 24 controls with primary osteoarthritis. Compared to controls, patients
with Paget's disease of bone presented higher levels of interleukin 6 and reduced interleukin 17, but levels of
tumoral necrosis factor α and interleukin 1 β did not differ signiﬁcantly. We found no signiﬁcant differences
when patients were compared according to disease activity or current treatment. There were no correlations
between cytokine levels and bone-speciﬁc alkaline phosphatase or extension of Paget's disease of bone on
bone scintigraphs. In conclusion, patients with PDB present signiﬁcant differences on levels of certain cytokines
in comparison to primary osteoarthritis patients, but these alterations did not appear to have a clear correlation
with parameters of disease activity or severity.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Paget's disease of bone (PDB) is a common osteometabolic disease
characterized by increased and disorganized bone turnover. It is usually
asymptomatic, but some patients may present bone pain, fractures,
deformities, secondary osteoarthritis, neurologic and cardiac complica-
tions and, in rare cases, neoplasm. It is believed that PDB is caused
by alterations in osteoclasts behavior, since pagetic bone is rich in
overactive osteoclasts and medications that act in these cells, as
bisphosphonates, are very effective in PDB [1,2].
PDB has a multifactorial etiology, genetic factors are clearly impor-
tant, about 15% of patients have a familial history, but environmental
factors, like viral infections [1,3], are also believed to play a role. The
most frequent genetic mutation associated with this disease is located
on sequestosome 1 (p62) gene, that is carried by 10–50% of patients
with familial PDB and by 5–30% of those with sporadic disease[1].
Sequestosome 1 is involved in signal transduction of many cytokines,
including receptor activator of nuclear factor kappa-B ligand (RANKL),
tumoral necrosis factor (TNF) α, nerve growth factor (NGF) and
interleukin(IL) 1 β, besides being involved in autophagy and apoptosis.
Other single nucleotide polymorphisms have been described to be
associated to PDB, most of them in proteins involved in osteoclast
differentiation and activation (but also important in other cells), suchHospital Governador Celso
lis/SC, Brazil, ZIP 88015-270
e Castro).
ghts reserved.as stimulating factor 1 (CSF-1) and tumor necrosis factor receptor
superfamily, member 11a (TNFRSF11A). [4,3,5].
As genetic mutations related to PDB occur in proteins that are also
important in immune cells and in signaling cascades of inﬂammatory
cytokines, alterations in cytokine levels would be expected to occur in
PDB patients. Moreover, osteoblasts and osteoclasts are also able to
secrete inﬂammatory cytokines, such as IL-6. In fact, high IL-6 levels
were reported in plasma and in affected bone from PDB patients [6,7],
although these ﬁndings were not replicated by some small studies
[8,9]. High IL-1 levels were also reported in osteoblasts from pagetic
bone [10] and in bonemarrowmonoclonal cells from PDB patients [11].
This study was undertaken to compare serum levels of the inﬂam-
matory cytokines TNF α, IL-1 β, IL-6 and IL-17 in PDB patients and in
patients without systemic inﬂammatory diseases and to identify factors
associated with any detected differences.
2. Methods
Consecutive patients with PDB followed by rheumatologists in
Florianopolis, Brazil, were included after signing an informed consent
term. Patients with primary osteoarthritis followed at the Rheumatolo-
gy Outpatient Clinic of Hospital Governador Celso Ramos from the same
age group (within up to 5 year difference from a PDB patient) and
matched for sex were recruited as controls. Patients with osteoarthritis
were chosen as controls because of the high prevalence of this disease in
the age group affected by PDB; most patients with PDB have concomi-
tant primary osteoarthritis. For both, patients and controls, exclusion
criteria were: systemic inﬂammatory diseases, active infections,
neoplasms, plurimetabolic syndrome, erosive osteoarthritis and current
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drugs (NSAIDs), corticosteroids, immunosuppressants, anti-cytokine
agents and any medication for osteoporosis, with exception of
bisphosphonates, calcitonin, calcium and vitamin D.
PDB and osteoarthritis were diagnosed by typical ﬁndings on X-rays.
Disease activity was evaluated by 99mTc MDP bone scintigraphs; a pa-
tient was considered to have active disease when bone scintigraph
shows high uptake suggestive of PDB and other possible diagnosis was
excluded by X-rays or other image techniques. All high uptake areas
were evaluated by X-rays or computed tomography. Disease extension
was determined by previous and recent X-rays and bone scintigraphs.
The method described by Meunier et al. [12] was used to calculate
disease extension on bone scintigraphs. A patient was considered
to be at current treatment if he had used oral bisphosphonates
(alendronate, risedronate or ibandronate) in the past 6 months or
zoledronic acid in the past 12 months. No patient has taken calcitonin,
intravenous ibandronate or pamidronate in the past 12 months.
Fasting blood samples were collected from patients and controls
with primary osteoarthritis for determination, by enzyme-linked
immunosorbent assay, of serum levels of: TNF α (BD Biosciences,
San Jose, CA, ref. 550610), and IL- 1 β (BD Biosciences, San Jose,
CA, ref. 557966), IL-6 (BD Biosciences, San Jose, CA, ref. 550799) and IL-
17(Raybiotech Inc., Norcross, GA, ref. ELH-IL17-001). Bone speciﬁc alka-
line phosphatase (BAP) (Mybiosource, San Diego, CA, ref. MBS724100)
was also measured in serum of PDB patients. Intra- and inter-assays
coefﬁcients of variation were: TNF-α: 4.90 ± 3.67% and 8.83 ±
6.13%, IL-1β = 2.01 ± 2.80% and 4.00 ± 4.5, IL-6 = 7.7 ± 6.70% and
7.70 ± 9.37%, IL-17 b10% and b12% and BAP b9% and b10%. For these
analyses, serum levels of cytokines in PDB patients were compared to
the results of controls with primary osteoarthritis. In order to identify
factors possibly associated to cytokine alterations, PDB patients were
further subdivided according to disease activity and treatment status.
We also searched for correlations between serum cytokines and disease
extension and BAP levels. Patients who received treatment with zoledro-
nic acid during the study periodwere submitted to a newblood collection
3 months after the infusion.
Results are presented as mean (standard deviation - SD) or percent-
age (95% conﬁdence interval). Comparisons between groups were done
with two-tailed Student's t-test. Correlations between linear variables
were analyzed by linear regression. Repeated measures were analyzed
with paired samples t-test. Statistical analysis was performed with
SPSS 18.0, with a level of signiﬁcance of 0.05.
Study protocol was approved by local ethical committee (protocol
number 353461). This study was conducted in accordance to
the principles of the Declaration of Helsinki (“WMA Declaration of
Helsinki - Ethical Principles for Medical Research Involving Human
Subjects,” n.d.).
3. Results
Fifty-one patients (mean age 66.9 ± 9.59 years), 75% females
(CI 95% 63.3–87.8) and 24 subjects with primary osteoarthritis (mean
age 62.42 ± 6.97 years), 83.3% females (CI 95% 62.7–86.3)were includ-
ed. Patients had a mean time from diagnosis of 10.45 ± 15.86 years;
55.1% (CI 95% 40.8–69.4) had a history of symptoms related to PDB,
28.6% (CI 95% 16.3–42.9) had monostotic disease and 44.9% (CI 95%
40.8–69.3) were considered to be in current treatment for PDB. Familial
history of PDB and presence of sequestosome 1 gene mutations were
both detected in 26.5% (CI 95% 14.3 – 39.2) of patients, 38.5% of patients
with familial PDB carried sequestosome 1 gene mutations.
There were no statistically signiﬁcant differences between
patients and controls with primary osteoarthritis in serum levels of
TNF α (85.68 ± 34.41 pg/ml vs 75.60 ± 34.04 pg/ml, p = 0.31)
and IL-1 (5.05 ± 2.94 pg/ml vs 4.43 ± 2.80 pg/ml, p = 0.391).
Patients with PDB presented higher serum levels of IL-6
(108.06 ± 71.07 pg/ml vs 72.03 ± 36.33 pg/ml, p = 0.024), whilecontrols with primary osteoarthritis controls presented higher levels
of IL-17 (78.56 ± 59.85 pg/ml vs 115.97 ± 56.70 pg/ml p = 0.012)
(Fig. 1). Because cytokine levels could differ between patients with ac-
tive and inactive disease, we compared these groups with controls,
but this approach revealed a similar pattern to the comparison between
controls and the whole group of patients (Table 1).
In order to investigate if cytokine levels were inﬂuenced by PDB ac-
tivity, we compared subgroups of patients divided according to disease
activity and to current treatment. We also searched for correlations be-
tween cytokine levels and disease extension and BAP levels. When pa-
tients were compared according to the presence of areas of high
uptake on bone scintigraphs, the only statistically signiﬁcant difference
between those with active (n 23) and inactive disease (n 28) was BAP
levels (p = 0.017) (Table 2). There were no statistically signiﬁcant dif-
ferences in cytokine levels between patients in current treatment (n 23)
and patients without current treatment (n 28), although levels of IL-6
were lower in patients in current treatment, this difference did not
achieve statistical signiﬁcance (p = 0.053) (Table 2). There were no
signiﬁcant correlations between BAP and cytokine levels (TNF α:
r = 0.053 p 0.713, IL-1 β: r = 0.134 p 0.349, IL-6: r = 0.09 p 0.532,
IL-17: r = 0.209 p 0.142) or between disease extension and cytokine
levels (TNF α: r = 0.179 p 0.204, IL-1 β: r = 0.308 p 0.027, IL-6:
r = 0.152 p 0.283, IL-17: r = 0.265 p 0.058), but BAP levelswere signif-
icantly correlated to disease extension (r = 0.515, p b 0.001).
During the study, seven patients with active PDB were treated with
zoledronic acid 5 mg and had their cytokines and BAP levels measured
before and 3 months after treatment. This interval was chosen to
avoid acute inﬂammatory reactions that can occur soon after infusions
of zoledronic acid. After the treatment, there were reductions in
values of TNF α, IL-1 β, IL-6 and BAP and increasing of IL-17 levels
(TNF α: 71.00 ± 31.42 pg/ml vs 51.33 ± 31.49 pg/ml, IL-1 β:
6.73 ± 3.6 pg/ml vs 3.39 ± 2.94 pg/ml, IL-6: 159.97 ± 56.80 pg/ml
vs 78.04 ± 47.11 pg/ml, IL-17: 89.60 ± 83.62 pg/ml vs 200.51 ±
54.70 pg/ml, BAP 37.06 ± 17.34 U/l vs 16.71 ± .98 U/l) (Fig. 2).
4. Discussion
Our results demonstrated that patients with PDB present higher
levels of IL-6, but lower levels of IL-17 in comparison to subjects with
primary osteoarthritis. There were no signiﬁcant differences in levels
of TNFα or IL-1 β. These results are not correlated to disease activity de-
termined by bone scintigraphs and there were no correlations between
cytokine levels and BAP or extent of areas of high uptake on bone
scintigraph. Interestingly, treatment of PDBwith zoledronic acid result-
ed in reductions in serum levels of TNF α, IL-1 β, IL-6 and in increate in
IL-17 levels.
Literature regarding inﬂammatory cytokines in PDB is scarce. There
is one published study that reported higher levels of serum IL-6 in
pagetic patients [6] and two other studies with opposite results, but
their samples were smaller than ours [8,9]. Besides the present one,
only one other study has reported serum levels of IL-1 β and TNF α
[13], in a small number of PDB patients they were not able to demon-
strate differences in serum levels of these cytokines in comparison to
controls. To the best of our knowledge, there are no previous studies
of serum levels of IL-17 in this population.
Increased serum IL-6 in PDB patients could be produced by the
pagetic bone itself, since IL-6 was demonstrated to be overexpressed
in osteoblasts and osteoclasts from involved bone, or by inﬂammatory
cells, which function could be altered by the same genetic mutations
that predispose to PDB. The last hypothesis seems attractive, as serum
levels of IL-6 or IL-17 were not correlated to either BAP levels or extent
of affected bone. However, treatment with zoledronic acid resulted in
marked reduction in serum levels of IL-6, IL-1 β and TNF α and in
increase in IL-17 levels. This signalizes that the source of cytokine
alterations should be bony tissue, the main target of bisphosphonates.
A possible hypothesis to explain these apparently contradictoryﬁndings
Fig. 1.Dosage of pro- inﬂammatory cytokines: TNF-α (A), IL-1β (B), IL-6 (C), IL-17 (D), in patientswith Paget's disease of bone (PDB) (n = 51) and controls (n = 24). Each dot represents
the results of an individual patient. Lines represent mean (SD).* = p b 0.05, comparisons were done with Student's t test. TNF-α: tumoral necrosis fator alpha, IL-1β: interleukin 1 beta
(B), IL-6: interleukin 6, IL-17: interleukin 17.
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spared by PDB could have an abnormal phenotype. This hypothesis is
attractive since the genetic alterations that predispose to PDB are
present in the entire skeleton and not only in the clinically affected
bones, but needs further investigation.
In a recent study, Gallone et al. did not ﬁnd associations between
polymorphism of IL1 α, IL-1 β, IL6 and TNFα and the occurrence of
PDB [14]. This ﬁnding suggests that alterations in IL-6 levels may be
due to other genes involved in the expression of this cytokine or to
viral infections believed to be important in pathogenesis of PDB, or to
an interaction of both factors. This latter hypothesis is favored by recent
ﬁndings that measles virus nucleocapsid protein causes increased
expression of IL-6. [15].
The reduction in IL-17 levels in PDB patients, and its elevation after
treatment, is more intriguing and deserves further research. Besides
being produced by Th17 lymphocytes, its main source, IL-17 has been
reported to be produced by other cells, like osteoblasts [16], but not
by osteoclasts. IL-6 is a fundamental cytokine in Th17 differentiation
[17], but concomitant action of other cytokines is needed for thisTable 1
Comparison of serum cytokines between controls and subgroups of PDB patients, divided accord
two-tailed Student's t-test. TNF-α: tumoral necrosis factor alpha, IL-1β: interleukin 1 beta, IL-6
Controls PDB with active disease (n 23) p values (compared t
TNF α (pg/ml) 75.60 72.66 0.745
Mean (SD) (34.04) (27.03)
IL-1 β (pg/ml) 4.43 6.03 0.066
Mean (SD) (2.80) (3.00)
IL-6 (pg/ml) 72.03 121.93 0.015
Mean (SD) (36.33) (86.79)
IL_17 (pg/ml) 115.97 94.95 0.231
Mean (SD) (56.70) (62.00)process. This could explain why high levels of IL-6 in PDB are not
reﬂected in IL-17 levels. Another possible explanation for this phenom-
enon could be a negative feedback from activated osteoclasts to Th17,
since IL-17 has a strong osteoclastogenic activity [17]. This feedback
could be exerted by substances like interferon β, a cytokine released
by osteoclasts [18] with negative effects on differentiation of Th17 lym-
phocytes [19].
The present study has some limitations. In clinical practice, the usual
method to evaluate PDB's activity is serum alkaline phosphatase level.
We were not able to assess disease activity by this method because
we chose to measure bone speciﬁc alkaline phosphatase by an ELISA
assay. But, as this assay is not used in clinical practice, we do not have
a cutoff for normal levels. However, some patients with PDB may pres-
ent bone pain and altered bone scintigraph while with serum alkaline
phosphatase level in the normal range. These patients usually get relief
of their symptoms after treatmentwith zoledronic acid. Thismeans that
not every patientwith active PDB can be identiﬁed only by high alkaline
phosphatase levels. Another limitation that should be taken into ac-
count while interpreting the results is the low number of subjectsing to disease activity. Results are presented asmedian (SD). Comparisonswere donewith
: interleukin 6, IL-17: interleukin 17.
o controls) PDB with inactive disease (n 28) p values (compared to controls)
94.37 0.195
(52.60)
4.71 0.859
(3.18)
108.68 0.023
(59.89)
68.03 0.015
(63.30)
Fig. 2. Dosage of pro-inﬂammatory cytokines: TNF-α (A), IL-1β (B), IL-6 (C), IL-17 (D) and b
treatment with zoledronic acid and after 3 months. Each line represents the results of an ind
interleukin 6, IL-17: interleukin 17, BAP: bone speciﬁc alkaline phosphatase.
Table 2
Comparison of serum cytokines and BAP levels in patients, according to disease activity
and to current treatment state. Results are presented as median (SD). Comparisons were
done with two-tailed Student's t-test. TNF-α: tumoral necrosis factor alpha, IL-1β: inter-
leukin 1 beta (B), IL-6: interleukin 6, IL-17: interleukin 17, BAP: bone speciﬁc alkaline
phosphatase.
Disease activity Current treatment
Active
(n 23)
Inactive
(n 28)
p values Yes
(n 23)
No
(n 28)
p values
TNF α (pg/ml) 72.66 94.37 0.09 89.03 82.69 0.601
Mean (SD) (27.03) (52.60) (43.56) (43.85)
IL-1 β (pg/ml) 6.03 4.71 0.195 5.63 4.53 0.179
Mean (SD) (3.00) (3.18) (2.93) (2.90)
IL-6 (pg/ml) 121.93 108.68 0.600 88.14 125.85 0.053
Mean (SD) (86.79) (59.89) (43.45) (85.75)
IL_17 (pg/ml) 94.95 68.03 0.194 73.23 83.33 0.545
Mean (SD) (62.00) (63.30) (54.86) (64.60)
BAP (U/l) 49.95 20.12 0.017 28.87 38.30 0.187
Mean (SD) (42.13) (8.16) (16.08) (39.89)
280 G.R. Werner de Castro et al. / International Immunopharmacology 18 (2014) 277–281in subgroups analyses. However, the results are consistent across all
analyses, whichmeans the probability that the results are due to chance
is low.
Another possible point of concern might be the option to use sub-
jectswith osteoarthritis as controls. This is justiﬁed because osteoarthri-
tis is very prevalent in the age group affected by PDB [20,21]. Therefore,
it is very difﬁcult to ﬁnd people aged over 60 yearswithout osteoarthri-
tis. Besides, many of those who do not have osteoarthritis have other
prevalent diseases in this age group, such as obesity, diabetes mellitus,
neoplasm, heart diseases. Most of the elder people with osteoarthritis
are asymptomatic and, in fact, could be considered “healthy” for most
studies. It should be emphasized that the majority of our controls
were asymptomatic, although they have radiographic evidences of
osteoarthritis, and that many of our PDB patients also have primary
osteoarthritis.
In conclusion, patients with PDB present signiﬁcant differences
on levels of IL-6 and IL-17 in comparison to controls with primaryone alkaline phosphate (BAP) (E) in 7 patients with Paget's disease of bone (PDB) pre-
ividual patient. TNF-α: tumoral necrosis fator alpha, IL-1β: interleukin 1 beta (B), IL-6:
281G.R. Werner de Castro et al. / International Immunopharmacology 18 (2014) 277–281osteoarthritis however, these alterations did not appear to have a clear
correlation with parameters of disease activity or severity.
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